Huiqin Xu

Huiqin Xu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2015 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
WDWei Du
Wei Du
YYYue Yuan
Yue Yuan
LWLin Wang
Lin Wang
YCYusi Cui
Yusi Cui
HWHui Wang
Hui Wang
GLGaolin Liang
Gaolin Liang

25 April 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
AXA-Lei Xu
A-Lei Xu
YXYang-Yang Xue
Yang-Yang Xue
WTWei-Tao Tao
Wei-Tao Tao
SWSi-Qi Wang
Si-Qi Wang
HXHuiqin Xu
Huiqin Xu
The heterogeneity of triple negative breast cancer (TNBC) results in the worst prognosis among breast cancer types, making its treatment strategy very challenging. A recent study showed that oleanolic acid (OA) has a radiosensitizing effect on tumor cells, but it does not show a good clinical effect when used alone in radiotherapy. The cytotoxicity of radiotherapy can be enhanced by modulating DNA repair, so new treatment options are being investigated to inhibit DNA repair pathways and sensitize tumors to radiation. Radiation induces DNA double-strand breaks (DSBs), and inhibition of Poly (ADP-Ribose) polymerase (PARP) can prevent the repair of these lesions. Hence, we evaluated the radiosensitization and the underlying mechanism of combination treatment with OA and olaparib in TNBC. Meanwhile, tumor hypoxia was monitored with 18F-Fluoroerythronitroimidazole (FETNIM) positron emission tomography/computed tomography (PET/CT) during radiosensitization therapy. Here, we found that OA and olaparib in combination with radiotherapy significantly inhibited cell proliferation compared with other groups. The results were observed using colony formation assays [sensitization enhancement ratios (SER) 1.16-1.65]. In vivo, tumor growth was significantly delayed in transplanted tumors receiving irradiation (IR) with OA and olaparib. 18F-FETNIM PET/CT can be utilized for tumor hypoxia monitoring and radiosensitization response evaluation. In conclusion, these results suggest that the combination of OA and olaparib with IR enhances the inhibition of MDA-MB-231 in cell culture and in mice, providing a potentially novel combination for the effective treatment of TNBC patients.

1 November 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
WYWenjing Yu
Wenjing Yu
FQFeng Qiao
Feng Qiao
XSXiaoyu Su
Xiaoyu Su
DZDan Zhang
Dan Zhang
HWHui Wang
Hui Wang
HXHuiqin Xu
Huiqin Xu
The aim of this study was to evaluate the application of 18F-flortanidazole (18F-HX4)/18F-fluoromisonidazole (18F-FMISO) - based micro positron emission tomography/computed tomography (PET/CT) for imaging of tumor hypoxia and radiotherapy-associated changes in mice. Radiotracer-based cellular uptake was performed to explore the correlation between radiotracer uptake and hypoxia state in cells. Animal models were established using subcutaneous injection of the human breast cancer line (MDA-MB-231) in a nude mouse. The effect of radiotherapy on tumor xenograft was assessed by measuring the tumor volume and mouse survival time. Meanwhile, mice with xenograft were imaged with 18F-FMISO and18F-HX4 PET/CT before and after radiotherapy. Tumor-to-normal muscle ratio (T/N) of 18F-FMISO and18F-HX4 maximum uptake was calculated by selecting a region of interest. Changes in tumor biology were assessed with immunohistochemical staining; T/N (18F-FMISO) and T/N (18F-HX4) were analyzed in relation to tumor volume, survival time, and the expression of tumor biomarkers, including hypoxia-inducible factor (HIF)-1α, glucose transporter (Glut-1) and the proliferation antigen Ki67. Higher tracer uptake (both 18F-FMISO and 18F-HX4) was observed in hypoxic cells compared to oxygenated cell. The in vivo study suggested that both T/N (18F-FMISO) and T/N (18F-HX4) were positively correlated with tumor hypoxia volume (p = 0.014 and p = 0.009, respectively), but negatively associated with survival time (p = 0.012 and p = 0.007, respectively). HIF-1α, Glut-1 and Ki67 expression in tumors were downregulated after radiotherapy. T/N (18F-HX4) was correlated with the expression of hypoxia marker HIF-1α in xenografts (r = 0.768, p = 0.025); while T/N (18F-FMISO) was moderately correlated with the expressions of Ki67 (r = 0.412, p = 0.041). No significant correlation was detected between Glut-1 expression and T/N (18F-FMISO) or T/N (18F-HX4) (r = 0.511, p = 0.097 and r=0.562, p = 0.126, respectively). Both 18F-HX4 and 18F-FMISO PET/CT can be used as biomarkers for tumor hypoxia and radiotherapy-associated changes. The clinical utilization of these two PET tracers needs to be further validated.

1 July 2016 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
HWHui Wang
Hui Wang
YZYu Zhang
Yu Zhang
WYWenjing Yu
Wenjing Yu
XZXuefeng Zhao
Xuefeng Zhao
YXYangyang Xue
Yangyang Xue
HXHuiqin Xu
Huiqin Xu
Objective The aim of this study was to elucidate the radiosensitizing mechanism of irisquinone (IQ) and evaluate the utility of 18F-fluorodeoxyglucose (18F-FDG) and 18F-fluoromisonidazole (18F-FMISO) PET/computed tomography (CT) in assessing the radiosensitizing effect of IQ. Materials and methods In an in-vitro experiment, C6 rat glioma cells were treated with IQ, radiation, or both. The viability and radiosensitivity of C6 cells were detected using the MTT assay and clonogenic survival assay. The expression of hypoxia-inducible factor-1α (HIF-1α) was evaluated by real-time PCR and western blot. In an in-vivo experiment, C6 rat glioma cells were implanted into the right flank of rats and treated with IQ, radiation, both, or no treatment. 18F-FDG and 18F-FMISO PET/CT images were obtained before and after treatment. The expression of HIF-1α was detected by immunohistochemistry staining. Results In the in-vitro experiment, the results of the MTT assay showed that the half-inhibition concentration (IC50) of IQ for normoxic and hypoxic C6 tumor cells was 17.2 and 21.0 nmol/l, respectively. Clonogenic survival assay showed that IQ could improve the radiosensitivity of both normoxic and hypoxic C6 tumor cells. When the concentration of irradiation was 20% IC50 (4.2 nmol/l), the sensitive enhancement ratio of normoxic and hypoxic C6 tumor cells was 1.18 and 1.33, respectively. The mRNA and protein expression levels of HIF-1α decreased significantly when treated with IQ plus radiation compared with the other groups. In the in-vivo experiment, 24 or 48 h after different treatments, the maximum standardized uptake values (SUVmax) of 18F-FDG or 18F-FMISO uptake decreased in the radiation group and the IQ plus radiation group, whereas these values increased in the control and IQ groups. The SUVmax of 18F-FDG or 18F-FMISO uptake in IQ plus radiation group were lower than those of the radiation group (t=3.28, 2.62, P<0.05). However, there was no significant decrease in tumor volumes in the radiation group and the IQ plus radiation treatment group early after treatment. Immunohistochemistry staining showed that there were significant differences in the expression of HIF-1α in the four groups (F=87.1, P<0.01). The SUVmax of both 18F-FDG and 18F-FMISO uptake showed a significant correlation with the expression of HIF-1α. 18F-FMISO provided a higher correlation coefficient with HIF-1α than 18F-FDG (r=0.93, 0.82, P<0.01). Conclusion The present experiments indicated that IQ enhanced the radiosensitivity of C6 rat glioma cells both in vitro and in vivo. The primary mechanism of this radiosensitizing effect involves the downregulation of HIF-1α. 18F-FDG and 18F-FMISO PET/CT were sensitive and noninvasive for monitoring the early radiosensitizing effect of IQ. Meanwhile, 18F-FMISO PET/CT provided more information on the changes in tumor hypoxic status.

30 October 2017 in Journal of Labelled Compounds and Radiopharmaceuticals
Verified
Journal Article
Closed access
PDF file
LLLili Liang
Lili Liang
XZXueqian Zhang
Xueqian Zhang
XSXiaoyu Su
Xiaoyu Su
JLJianchun Li
Jianchun Li
YTYong Tian
Yong Tian
HXHuiqin Xu
Huiqin Xu

28 April 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
HWHui Wang
Hui Wang
YMYing Miao
Ying Miao
WYWenjing Yu
Wenjing Yu
GZGan Zhu
Gan Zhu
TWTao Wu
Tao Wu
HXHuiqin Xu
Huiqin Xu
Objective: We sought to explore the feasibility of shorter acquisition times using two short dynamic scans for a multiparametric PET study and the influence of quantitative performance in shortened dynamic PET.Methods: Twenty-one patients underwent whole-body dynamic 18F-FDG PET/CT examinations on a PET/CT (Siemens Biograph Vision) with a total scan time of 75 min using continuous bed motion for Patlak multiparametric imaging. Two sets of Patlak multiparametric images were produced: the standard MRFDG and DVFDG images (MRFDG-std and DVFDG-std) and two short dynamic MRFDG and DVFDG images (MRFDG-tsd and DVFDG-tsd), which were generated by a 0–75 min post injection (p.i.) dynamic PET series and a 0–6 min + 60–75 min p.i. dynamic PET series, respectively. The maximum, mean, and peak values of the standard and two short dynamic multiparametric acquisitions were obtained and compared using Passing–Bablok regression and Bland–Altman analysis.Results: High correlations were obtained between MRFDG-tsd and MRFDG-std, and between DVFDG-tsd and DVFDG-std for both normal organs and all lesions (0.962 ≦ Spearman’s rho ≦ 0.982, p < 0.0001). The maximum, mean, and peak values of the standard and two short dynamic multiparametric acquisitions were also in agreement. For normal organs, the Bland–Altman plot showed that the mean bias of MRFDG-max, MRFDG-mean, and MRFDG-peak was -0.002 (95% CI: -0.032–0.027), -0.002 (95% CI: -0.026–0.023), and -0.002 (95% CI: -0.026–0.022), respectively. The mean bias of DVFDG-max, DVFDG-mean, and DVFDG-peak was -3.3 (95% CI: -24.8–18.2), -1.4 (95% CI: -12.1–9.2), and -2.3 (95% CI: -15–10.4), respectively. For lesions, the Bland–Altman plot showed that the mean bias of MRFDG-max, MRFDG-mean, and MRFDG-peak was -0.009 (95% CI: -0.056–0.038), -0.004 (95% CI: -0.039–0.031), and -0.004 (95% CI: -0.036–0.028), respectively. The mean bias of DVFDG-max, DVFDG-mean, and DVFDG-peak was -8.4 (95% CI: -42.6–25.9), -4.8 (95% CI: -20.2–10.6), and -4.0 (95% CI: -23.7–15.6), respectively.Conclusions: This study demonstrates the feasibility of using two short dynamic scans that include the first 0–6 min and 60–75 min scans p.i. for Patlak multiparametric images, which can increase patient throughout for parametric analysis.